Dexcom (DXCM) — insider trading
Health Care
Dexcom (DXCM) has 14 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 14 (latest 2026-07-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | Brown Michael Jon | Officer (EVP Chief Legal Compliance Off) | Open-market sale | 1,700 | $74.42 | $126.5K | Form 4 |
| 2026-07-06 | SAYER KEVIN R | Director, Officer (Executive Chair) | Open-market sale | 26,756 | $72.00 | $1.93M | Form 4 |
| 2026-06-15 | FOLETTA MARK G | Director | Open-market sale | 199 | $74.82 | $14.9K | Form 4 |
| 2026-06-15 | FOLETTA MARK G | Director | Open-market sale | 3,801 | $74.10 | $281.7K | Form 4 |
| 2026-06-15 | Brown Michael Jon | Officer (EVP Chief Legal Compliance Off) | Open-market sale | 1,700 | $75.55 | $128.4K | Form 4 |
| 2026-06-04 | Coleman Jon | Officer (EVP, Chief Commercial Officer) | Open-market sale | 4,911 | $74.13 | $364.1K | Form 4 |
| 2026-06-03 | Coleman Jon | Officer (EVP, Chief Commercial Officer) | Open-market sale | 4,912 | $73.00 | $358.6K | Form 4 |
| 2026-05-28 | Driscoll Rimma | Director | Grant / award / vesting | 5,605 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Osterloh Albert Frederick IV | Director | Grant / award / vesting | 1,630 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Heller Bridgette P | Director | Grant / award / vesting | 5,575 | $0.00 | $0 | Form 4 |
| 2026-05-28 | FOLETTA MARK G | Director | Grant / award / vesting | 6,331 | $0.00 | $0 | Form 4 |
| 2026-05-28 | AUGUSTINOS NICHOLAS | Director | Grant / award / vesting | 5,575 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Malady Kyle | Director | Grant / award / vesting | 5,575 | $0.00 | $0 | Form 4 |
| 2026-05-28 | ALTMAN STEVEN R | Director | Grant / award / vesting | 5,565 | $0.00 | $0 | Form 4 |
Ask the chat about DXCM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Dexcom (DXCM).
Last updated 2026-07-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.